Cancer epidemiology and the workplace

Salud Publica de Mexico

Volumn 39, Issue 4, 1997, Pages 356-368

  Frumkin, Howard ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Neoplasms working risks; Review

Indexed keywords

CARCINOGEN;

CANCER CONTROL; CANCER EPIDEMIOLOGY; CARCINOGENICITY; DEVELOPING COUNTRY; HUMAN; OCCUPATIONAL CANCER; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; REVIEW; UNITED STATES; WORKPLACE;

EID: 0030963735     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0036-36341997000400013     Document Type: Review

References (106)

1. Doll R, Peto R. The causes of cancer. Nueva York: Oxford University Press, 1981.
2. Higginson J. Environmental carcinogenesis Cancer 1993;72suppl 3:971-977.
3. Drinkwater NR. Experimental models and biological mechanisms for tumor promotion. Cancer Cell 1990;2:8-15.
4. Farber E. The multistep nature of cancer development. Cancer Res 1984;44:4217-4223.
5. Sugimura T. Multistep carcinogenesis: A 1992 perspective. Science 1992,258:603-607.
6. Vainio H, Husgafvel-Pursiainen. Mechanisms of carcinogenesis and molecular epidemiology. Br J Hosp Med 1996;56:162-170.
7. Fearon ER, Vogelstein BA A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
8. Lane DP. On the expression of the p53 protein in human cancer. Mol Biol Rep 1994;19:23-29.
9. Harris CC. The 1995 walter hubert lecture. Molecular epidemiology of human cancer: Insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer 1996;73:261-269.
10. González FJ, Crespi CL, Gelboin HV. DNA-expressed human cytochrorne P450s:A new age of molecular toxicology and human risk assessment. Mutat Res 1991;247:113-127.
11. Pelkonen O. Carcinogen metabolism and individual susceptibility. Scand J Work Environ Health 1992,18suppl:17-21.
12. Van Duuren BL, Banerjee S. Thresholds in chemical carcinogenesis. J Am Coll Toxicol 1984;2:85.
13. Environmental Protection Agency. Special report on environmental endocrine disruption: An effects assessment and analysis. EPA/630/R-96/012. Washington, D.C.: US, EPA, 1997.
14. David DL, Bradlow HL, Wolff M et al. Medical hypothesis: Xenoestrogens as preventable causes of breast cancer. Environ Health Perspect 1993;101:372-377.
15. Toppari J, Larsen JC, Christiansen P et al. Male reproductive health and environmental chemicals with estrogenic effects. Miljoprojekt nr. 290. Report of the Ministry of Environment and Energy, Danish Environmental Protection Agency, Copenhagen, 1995.
16. Jick H, Watkins RN, Hunter JR et al. Replacement estrogens and endometrial cancer. N Engl J Med 1979;300:218-222.
17. Wolff MS, Toniolo PG, Lee EW et al. Blood levels of organochlorine reisdues and risk of breast cancer. J Natl Cancer Inst 1993;85:648-652.
18. Krieger N, Wolff MS, Hiatt RA et al. Breast cancer and serum organochlorines: A prospective study among white, black, and Asian women. J Natl Cancer Inst 1994;86:589-599.
19. Blair A, Zahm SH. Agricultural exposures and cancer. Environ Health Perspect 1995,103suppl 8:205-208.
20. Coward I, Barnes NC, Setchell KDR et al. Genistein, daidzein, and their b-glycoside conjugates:Antitumor isoflavones in soybean foods from American and Asian diets. J Agric Food Sci 1993;41:1961-1967.
21. Rothman KJ. Modern epidemiology. Boston: Little, Brown, 1986.
22. Kelsey JL, Whittemore AS, Evans AS, Thompson WD. Methods in observational epidemiology, 2a.edición. Nueva York: Oxford University Press, 1996.
23. Monson R. Occupational epidemiology. 2a. edición. Boca Raton: CRC Press, 1990.
24. Checkoway H, Pearce NE, Crawford-Brown DJ. Research methods in occupational epidemiology. Nueva York: Oxford University Press, 1989.
25. Jaffe M. Validity of exposure data derived from a structured questionnaire. Am J Epidemiol 1992;135:564-570.
26. Ahlborg GA. Validity of exposure data obtained by questionnaire. Scand J Work Environ Health 1990;16:284-288.
27. Lerchen ML, Samet JM. An assessment of the validity of questionnaire responses provided by a surviving spouse. Am J Epidemiol 1986;123:481-489.
28. Coggon D, Pippard EC, Acheson ED. Accuracy of occupational histories obtained from wives. Br J Ind Med 1985;42-563-564
29. Bouyer J, Hémon D. Retrospective evaluation of occupational exposures in population-based case-control studies: General overview with special attention to job exposure matrices. Int J Epidemiol 1993;22suppl 2:57S-64S.
30. Siemiatycki J, Dewar R, Richardson L. Costs and statistical power associated with five methods of collecting occupation exposure information for population-based case-control studies. Am J Epidemiol 1989;130:1236-1246.
31. Hoar SK, Morrison AS, Cole P, Silverman DT. An occupation and exposure linkage system for the study of occupational carcinogenesis. J Occup Med 1980;22:722-726.
32. Medical Research Council, Environmental Epidemiology Unit. Job exposure matrices. Proceedings of a Conference held in April, 1982 at the University of Southampton. Scientific Report núm. 2. Southampton: Southamptom General Hospital, 1983.
33. Acheson ED. What are job exposure matrices? En: Medical Research Council, Environmental Epidemiology Unit. Job Exposure Matrices. Proceedings of a Conference held in April, 1982 at the University of Southampton. Scientific Report núm 2. Southampton: Southamptom General Hospital, 1983:1-4.
34. Pannett B, Coggon D, Acheson ED. A job-exposure matrix for use in population based studies in England and Wales. Br J Ind Med 1985;42:777-783.
35. Ferrario F, Continenza D, Pisani P et al. Description of a job-expsoure matrix for sixteen agents which are or may be related to respiratory-cancer. En: Hogstedt C, Reuterwall C, ed. Progress in occupational epidemiology: Proceedings of the Sixth International Symposium on Epidemiology in Occupational Health. Stockholm: Excerpta Medica, 1988:379-382.
36. Sieber WK, Sundin DS, Frazier TM. Development, use, and availability of a job exposure matrix based on national occupational hazard survey data. Am J Ind Med 1991;20:163-174.
37. Post WK, Heederik D, Kromhout H, Kromhout D. Occupational exposures estimated by a population specific job exposure matrix and 25 year incidence rate of chronic nonspecific lung disease (CNSLD): The Zutphen Study. Eur Respir J 1994;7:1048-1055.
38. Kromhout H, Loomis DP, Mihlan GJ et al. Assessment and grouping of occupations magnetic field exposures in five electric utility companies. Scand J Work Environ Health 1995;21:43-50.
39. Glass DC, Spurgeon A, Calvert IA et al. Retrospective assessment of solvent exposure in paint manufacturing. Occup Environ Med 1994;51:617-625.
40. Moulin JJ, Romazini S, Lasfargues G et al. Development of a job-exposure matrix in the heavy-metal industry in France. Rev Epidemiol Sante Publique 1997;45(1):41-51.
41. Gómez MR, Cocco P, Dosemeci M, Stewart PA. Occupational exposure to chlorinated aliphatic hydrocarbons: Job exposure matrix. Am J Ind Med 1994;26:171-183.
42. Hémon D, Bouyer J, Berrino F et al. Retrospective evaluation of occupational exposures in cancer epidemiology:A European concerted action of research. Appl Occup Environ Hyg 1991;6:541-546.
43. Stewart PA, Herrick RF. International workshop on retrospective exposure assessment for occupational epidemiologic studies. Preface. Appl Occup Environ Hyg 1991,6:417-420.
44. Bouyer J, Hémon D. Comparison of three methods of estimating odds ratios from a job exposure matrix in occupational case-control studies. Am J Epidemiol 1993;137:472-481.
45. Dosemeci M, Cocco P, Gomez M et al. Effects of three features of a job-exposure matrix on risk estimates. Epidemiology 1994;5:124-127.
46. Cocco P, Dosemeci M, Gómez MR et al. A retrospective evaluation of exposure to dichloromethane by using a job-exposure matrix. Med Lavoro 1994;85:84-87.
47. Bouyer J, Dardenne J, Hémon D. Performance of odds ratios obtained with a job-exposure matrix and individual exposure assessment with special reference to misclassification errors. Scand J Work Environ Health 1995;21:265-271.
48. Rybicki BA, Johnson CC, Peterson EL et al. Comparability of different methods of retrospective exposure assessment of metals in manufacturing industries. Am J Ind Med 1997;31:36-43.
49. Messing K, Dumais L, Courville J et al. Evaluation of exposure data from men and women with the same job title. J Occup Med 1994;36:913-917.
50. Hulka BS, Wilcosky TC, Griffith JD. Biological markers in epidemiology. Nueva York: Oxford University Press, 1990.
51. Mercier MJ, Robinson AE. Use of biologic markers for toxic end-points inassessment of risks from exposure to chemicals. Int Arch Occup Environ Health 1993;65:7S-10S.
52. National Research Council Biologic markers in pulmonary toxicology. Washington, D.C.: National Academy Press, 1989.
53. Perera F, Weinstein IB. Molecular epidemiology and carcinogen-DNA adduct detection: New approaches to studies of human cancer causation. J Chronic Dis 1982;35:581-600.
54. Wogan GN. Markers of exposure to carcinogens. Environ Health Perspect 1989;81:9-17.
55. Groopman JD, Skipper PL. Molecular dosimetry and human cancer: Analytical, epidemiological, and social considerations. Boca Raton: CRC Press, 1991.
56. Törnqvist M, Landin HH. Hemoglobin aducts for in vivo dose monitoring and cancer risk estimation. J Occup Environ Med 1995;37:1077-1085.
57. Cale CM, Garner RC. Measurement of DNA adducts in humans after complex mixture exposure. Food Chem Toxicol 1996;34:905-919.
58. Hemminki K. Use of molecular biology techniques in cancer epidemiology. Scand J Work Environ Health 1992;18suppl 1:38-45.
59. De Vivo I, Marion M-J, Smith SJ et al. Mutant c-Ki-ras p21 protein in chemical carcinogenesis in humans exposed to vinyl chloride. Cancer Causes Control 1994;5:273-278.
60. Hollstein M, Marion M-J, Lehman T et al. P53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 1994;15.1-3.
61. Brandt-Rauf P, Smith S, Perera F et al. Serum oncogene proteins in foundry workers. J Soc Occup Med 1990,40:11-14.
62. Brandt-Rauf PW, Niman HL. Serum screening for oncogene proteins in workers exposed to PCBs. Br J Ind Med 1988;45:689-693.
63. Rothman N, Hayes RB. Using biomarkers of genetic susceptibility to enhance the study of cancer etiology. Environ Health Perspect 1995;103suppl 8:291-295.
64. Percy C, Stanek E, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics.Am J Public Health 1981;71:242-250.
65. Lee PN. Comparison of autopsy, clinical and death certificate diagnosis with particular reference to lung cancer. A review of the published data. Apmis 1994;45suppl: 1-42.
66. Shackleton S, Harrington JM. Non-occupational factors in occupational morbidity and mortality. Pol J Occup Med 1989;2:105-130.
67. McWhorter WP, Schatzkin AG, Horm JW, Brown CC. Contribution of socioeconomic status to black/white differences in cancer incidence. Cancer 1989;63:982-987.
68. Baqute CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst 1991;83:551-557.
69. Freman H. Race, poverty and cancer. J Natl Cancer Inst 1991;83:526-527
70. Giovino GA, Henningfield JE. Tomar SL et al. Epidemiology of tobacco use and dependence. Epidemiol Rev 1995;17:48-65.
71. Siemiatycki J, Wacholder S, Dewar R et al. Degree of confounding bias related to smoking, ethnic group, and socioeconomic status in estimates of the associations between occupation and cancer. J Occup Med 1988;30:617-625.
72. McMichael AJ. Standardized mortality ratios and the "healthy worker effect:" Scratching beneath the surface. J Occup Med 1976;18:165-168.
73. Fox AJ, Collier PF Low mortality rates in industrial cohort studies due to selection for work and survival in the industry. Br J Prev Soc Med 1976;30:225-230.
74. Arrighi HM, Hertz-Picciotto I. The evolving concept of the healthy worker survivor effect Epidemiology 1994;5:189-196
75. Pearce N, Checkoway H, Shy C. Time-related factors as potential confounders and effect modifiers in studies based on an occupational cohort. Scand J Work Environ Health 1986;12:97-107.
76. Choi BC. Definition, sources, magnitude, effect modifiers, and strategies of reduction of the healthy worker effect. J Occup Med 1992;34:979-988.
77. Arrighi HM, Hertz-Picciotto I. Controlling the healthy worker survivor effect: an example of arsenic exposure and respiratory cancer. Occup Environ Med 1996;53:455-462.
78. Robins J. A new approach to causal inference in mortality studies with a sustained exposure period-application to control of the healthy worker survivor effect. Math Modeling 1986;7:1393-1512.
79. Berry G, Newhouse ML, Antonis P. Combined effects of asbestos exposure and smoking on mortality from lung cancer and mesothelioma in factory workers. Br J Ind Med 1985;42:12-18.
80. Hammond EC, Selikoff IJ, Seidman H. Asbestos exposure, cigarette smoking and death rates. Ann NY Acad Sci 1979;330:473-490.
81. Rothman KJ. Interactions between causes. En: Modern epidemiology. Boston: Little Brown, 1986:311-326.
82. International Agency for Research on Cancer IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Suppl. 7. Overall Evaluations of Carcinogenicity:An Updating of IARC Monographs Volumes I to 42. Lyon: IARC, 1987;1-42suppl 7.
83. Stellman JM, Stellman SD. Cancer and the workplace. CA Cancer J Clin 1996;46:70-92.
84. Pearce N, Matos E, Vainio H, Boffetta P, Kogevinas M, ed. Occupational cancer in developing countries. IARC Scientific Publication núm. 129. Lyon: IARC, 1994.
85. Vainio H, Matos E, Boffetta P et al. Occupational cancer in developing and newly industrialized countries. Ann Acad Med Singapore 1993;22:170-181.
86. Levy BS, Seplow A. Asbestos-related hazards in developing countries. Environ Res 1992;59(1).167-174.
87. Huncharek M. Exporting asbestos: Disease and policy in the developing world. J Public Health Policy 1993;14:51-65.
88. Lernen RA, Bingham E. A case study in avoiding a deadly legacy in developing countries. Toxicol Ind Health 1994;10(1-2):59-87.
89. Jeyaratnam J. Health problems of pesticide use in the third world. Br J Ind Med 1985;42:505-506.
90. Castleman BI, Navarro V. International mobility of hazardous products, industries, and wastes. Ann Rev Public Health 1987;8:1-19.
91. Castleman BI. The migration of industrial hazards. Int J Occup Environ Health 1995;1:85-96.
92. Loewenson R. Occupational health epidemiology in Africa: Drought on fertile grounds. Int J Occup Environ Health 1995;1:260-268.
93. Xu X, Christiani DC. Occupational health research in developing countries: Focus on US-China collaboration. Int J Occup Environ Health 1995;1:136-141.
94. Kjellstrom T, Rosenstock L. The role of environmental and occupational hazards in the adult health transition. World Health Stat Q 1990;43:188-196.
95. Natinal Research Council. Risk assessment in the federal government: Managing the process. Washington, D.C.: National Academiy Press, 1983.
96. Morrison AS. Screening in chronic disease. 2a. edición. Nueva York: Oxford Univesity Press, 1992.
97. Halperin WE, Ratcliffe J, Frazier TM et al. Medical screening in the workplace: proposed principles. J Occup Med 1986;28:547-552.
98. Schulte PA, Halperin WE, Ward EM, Ruder AM. Bladder cancer screening in high-risk groups. J Occup Med 1990;32:787-945.
99. Choi BC, Connolly JG, Zhou RH. Application of urinary mutagen testing to detect workplace hazardous exposure and bladder cancer. Mutat Res 1995;341(3):207-216.
100. Esteve A, Sorlie T, Martel-Planche G et al. Screening for p53 gene mutations in archived tumors of workers occupationally exposed to carcinogens: examples from analysis of bladder tumors. J Occup Environ Med 1995;37(1):59-68.
101. Marsh GM, Leviton LC, Talbott EO et al. Drake chemical workers' health registry: Notification and medical surveillance of a group of workers at high risk of developing bladder cancer. Am J Ind Med 1991;19:291-301.
102. The National Cancer Institute Cooperative Early Lung Cancer Detention Program. Summary and conclusions. Am Rev Resp Dis 1984;130:565-567.
103. US Preventive Services Task Force. Screening for lung cancer. In: Guide to Clinical Preventive Services. 2a. edición. Filadelfia: Williams & Wilkins, 1996:135-39.
104. Tockman MS. Clinical detection of lung cancer progression markers, J Cell Biochem Suppl 1996;25:177-184.
105. Mulshine JL, Scott F. Molecular markers in early cancer detection. New screening tools. Chest 1995;107suppl 6:280S-286S.
106. Brennan TA. Untangling causation issues in law and medicine: Hazardous substance litigation.Ann Int Med 1987;107:741-747.